INOVIQ Ltd (ASX:IIQ)

Market Cap	47.86M -14.2%
Revenue (ttm)	1.82M +16.3%
Net Income	-6.93M
EPS	-0.06
Shares Out	140.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,668
Average Volume	109,106
Open	0.3500
Previous Close	0.3500
Day's Range	0.3400 - 0.3500
52-Week Range	0.3200 - 0.6900
Beta	2.50
RSI	36.12
Earnings Date	Feb 18, 2026

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of can...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IIQ

Financial Performance

In fiscal year 2025, INOVIQ's revenue was 1.82 million, an increase of 16.25% compared to the previous year's 1.56 million. Losses were -6.93 million, 5.77% more than in 2024.